大学ホーム医学部教員紹介田口 慧

教員紹介:田口 慧

氏名
 
田口 慧
タグチ サトル TAGUCHI, Satoru
職位 助教
学内の役職・委員等 手術部運営委員、臨床研修係、がんゲノム医療推進委員
所属教室 泌尿器科学
専攻・専門分野
 (大学院)
外科系専攻 泌尿器科学分野
専門分野 泌尿器腫瘍学
研究テーマ 1. 後腹膜悪性腫瘍(泌尿器癌・肉腫等)に対するウイルス療法の開発
2. 臨床データベースを用いた、泌尿器癌のコホート研究
略歴 平成20年 東京大学医学部 卒業
平成20年~22年 三井記念病院 初期臨床研修医
平成22年~23年 三井記念病院 泌尿器科医員
平成23年~24年 東京大学医学部 泌尿器科助教
平成24年~26年 東京逓信病院 泌尿器科医員
平成26年~30年 東京大学大学院 (泌尿器科病院診療医を兼務)
平成30年~ 杏林大学医学部 泌尿器科助教

【受賞】
平成31年 日本泌尿器科学会 総会賞
平成29年 日本泌尿器科学会 総会賞
平成29年 日本泌尿器科学会 ヤングリサーチグラント
平成27年 日本癌治療学会 優秀演題賞
所有する学位 博士(医学)
指導医・専門医・認定医、その他の資格等 日本泌尿器科学会専門医・指導医
日本がん治療認定医機構 がん治療認定医
がんプロフェッショナル養成基盤推進プラン 修了
ぼうこうおよび直腸機能障害指定医
ロボット(da Vinci Si)手術認定医
論文・著書等を含む主要研究業績 英文
42. Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T, Nakagawa K, Abe O, Kume H, Fukuhara H*. Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: comparison of front-line therapies for localized prostate cancer. Radiother Oncol 2019; 140: 62-67.
41. Samejima M, Taguchi S*, Miyagawa S, Matsumoto R, Omura S, Ninomiya N, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Okegawa T, Koba T, Matsuki R, Jimbo I, Motoyasu A, Tsumura T, Shimoyamada H, Shibahara J, Sakamoto Y, Fukuhara H. Acute hypotension induced by suction of cystic fluid containing extremely high concentrations of catecholamines during resection of giant pheochromocytoma. IJU Case Rep 2019, in press.
40. Taguchi S, Nakagawa T*, Fukuhara H. Re: Jurgen E. Gschwend, Matthias M. Heck, Jan Lehmann, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11. Eur Urol 2019, in press.
39. Taguchi S, Fukuhara H*, Todo T. Oncolytic virus therapy in Japan: Progress in clinical trials and future perspectives. Jpn J Clin Oncol 2018, in press.
38. Fujimura T*, Fukuhara H, Yamada Y, Taguchi S, Sugihara T, Niimi A, Nakamura M, Nakagawa T, Igawa Y, Homma Y, Kume H. Aggressive Cancer Behavior of Latent Gleason Pattern 5 in Prostatectomy Specimens. Anticancer Res 2018; 38(11): 6529-6535.
37. Taguchi S, Fukuhara H*, Miyakawa J, Morikawa T, Naito A, Kawai T, Fujimura T, Kume H. Prognostic significance of neutrophil-to-lymphocyte ratio in collecting duct carcinoma. Jpn J Clin Oncol 2018; 48(7): 692-694.
36. Miyakawa J, Taguchi S*, Suzuki M, Endo K, Nose Y, Sato T, Ishikawa A, Fukuhara H, Homma Y. Impact of monthly 120 mg denosumab on bone metabolism in bone-metastatic prostate cancer undergoing androgen deprivation therapy. Asian Pac J Cancer Care 2017; 2(3): 55-60.
35. Otsuka M, Taguchi S, Nakagawa T*, Morikawa T, Maekawa S, Miyakawa J, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Clinical significance of random bladder biopsy in primary T1 bladder cancer. Mol Clin Oncol 2018; 8: 665-70.
34. Sato M, Taguchi A*, Fukui Y, Kawata A, Taguchi S, Kashiyama T, Eguchi S, Inoue T, Tomio K, Tanikawa M, Sone K, Mori M, Nagasaka K, Adachi K, Ikemura M, Domoto Y, Arimoto T, Oda K, Fukayama M, Osuga Y, Fujii T. Blood vessel invasion is a strong predictor of postoperative recurrence in endometrial cancer. Int J Gynecol Cancer 2018; 28: 875-81.
33. Matsumoto A, Nakagawa T*, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. World J Urol 2018; 36: 249-56.
32. Taguchi S*. Editorial Comment from Dr Taguchi to Demographics, managements, and treatment outcomes of benign and malignant retroperitoneal tumors in Japan. Int J Urol 2018; 25: 67-8.
31. Buti S, Puligandla M, Bersanelli M*, DiPaola R, Manola J, Taguchi S, Haas NB. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol 2017; 28: 2747-53.
30. Nakagawa T*, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate? Ann Surg Oncol 2017; 24: 2794-800.
29. Fujimura T*, Fukuhara H, Taguchi S, Yamada Y, Sugihara T, Nakagawa T, Niimi A, Kume H, Igawa Y, Homma Y. Robot-assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy. BMC Cancer 2017; 17: 454.
28. Nakagawa T*, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J Urol 2017; 35: 1569-75.
27. Taguchi S, Fukuhara H*, Homma Y. Re: Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival: A. Abugharib, W. C. Jackson, V. Tumati, R. T. Dess, J. Y. Lee, S. G. Zhao, M. Soliman, Z. S. Zumsteg, R. Mehra, F. Y. Feng, T. M. Morgan, N. Desai and D. E. Spratt. J Urol 2017; 197: 662-668. J Urol 2017; 198: 212-4.
26. Taguchi S, Fukuhara H*, Homma Y, Todo T. Current status of clinical trials assessing oncolytic virus therapy for urological cancers. Int J Urol 2017; 24: 342-51.
25. Taguchi S, Buti S, Fukuhara H*, Otsuka M, Bersanelli M, Morikawa T, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Benefit of Adjuvant Immunotherapy in Renal Cell Carcinoma: a Myth or a Reality? PLoS One 2017; 12: e0172341.
24. Nakagawa T*, Taguchi S, Uemura Y, Kanatani A, Ikeda M, Matsumoto A, Yoshida K, Kawai T, Nagata M, Komemushi Y, Suzuki M, Enomoto Y, Nishimatsu H, Ishikawa A, Nagase Y, Kondo Y, Tanaka Y, Okaneya T, Hirano Y, Minowada S, Shinohara M, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder. Urol Oncol 2017; 35: 457.e15-21.
23. Tsuda Y, Nakagawa T*, Shinoda Y, Kanatani A, Kawai T, Taguchi S, Yamada Y, Sawada R, Kume H, Homma Y, Tanaka S, Kawano H. Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis. Int J Clin Oncol 2017; 22: 548-53.
22. Makino K, Nakagawa T*, Kanatani A, Kawai T, Taguchi S, Otsuka M, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Biphasic decline in renal function after radical cystectomy with urinary diversion. Int J Clin Oncol 2017; 22: 359-65.
21. Taguchi S, Fukuhara H*, Morikawa T, Matsumoto A, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible? Jpn J Clin Oncol 2016; 46: 1143-7.
20. Taguchi S, Shiraishi K, Fukuhara H*, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y. Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial? Radiat Oncol 2016; 11: 102.
19. Naito A, Taguchi S, Nakagawa T*, Matsumoto A, Nagase Y, Tabata M, Miyakawa J, Suzuki M, Nishimatsu H, Enomoto Y, Takahashi S, Okaneya T, Yamada D, Tachikawa T, Minowada S, Fujimura T, Fukuhara H, Kume H, Homma Y. Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder. World J Urol 2017; 35: 97-103.
18. Taguchi S, Shiraishi K, Fukuhara H*, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer. Int J Clin Oncol 2016; 21: 975-80.
17. Taguchi S, Nakagawa T*. Re: Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma: H. Fukushima, Y. Nakanishi, M. Kataoka, K. Tobisu and F. Koga. J Urol 2016; 195: 26-32. J Urol 2016; 195: 1951-2.
16. Taguchi S, Kume H, Fukuhara H*, Morikawa T, Kakutani S, Takeshima Y, Miyazaki H, Fujimura T, Nakagawa T, Ishikawa A, Igawa Y, Homma Y. Symptoms at diagnosis as independent prognostic factors in retroperitoneal liposarcoma. Mol Clin Oncol 2016; 4: 255-60.
15. Taguchi S, Fukuhara H*, Shiraishi K, Nakagawa K, Morikawa T, Kakutani S, Takeshima Y, Miyazaki H, Fujimura T, Nakagawa T, Kume H, Homma Y. Radical Prostatectomy versus External Beam Radiotherapy for cT1-4N0M0 Prostate Cancer: Comparison of Patient Outcomes Including Mortality. PLoS One 2015; 10: e0141123.
14. Otsuka M, Taguchi S, Nakagawa T*, Kawai T, Morikawa T, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Lower ureteral lesion is an independent predictor of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 2016; 34: 59.e9-13.
13. Taguchi S, Akamatsu N, Nakagawa T*, Gonoi W, Kanatani A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma. Clin Genitourin Cancer 2016; 14: 237-43.
12. Taguchi S, Nakagawa T*, Uemura Y, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Fujimura T, Fukuhara H, Kume H, Homma Y. Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world. World J Urol 2016; 34: 163-71.
11. Taguchi S*, Kishida Y, Tamura K, Nose Y, Sato T, Ishikawa A, Homma Y, Yamakawa M. Intrapelvic bulky tumor as an unusual presentation of Erdheim-Chester disease. Intern Med 2015; 54: 3241-5.
10. Taguchi S, Nakagawa T*, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Uemura Y, Fujimura T, Fukuhara H, Kume H, Homma Y. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: a multi-institutional study. Int J Urol 2015; 22: 638-43.
9. Taguchi S, Fukuhara H*, Kakutani S, Takeshima Y, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Igawa Y, Kume H, Homma Y. Risk factors for clinical metastasis in men undergoing radical prostatectomy and immediate adjuvant androgen deprivation therapy. Asian Pac J Cancer Prev 2014; 15: 10729-33.
8. Kakutani S, Fukuhara H, Taguchi S, Nagata M, Niimi A, Hattori M, Miyazaki H, Fujimura T, Nakagawa T, Kume H*, Igawa Y, Homma Y. Combination of docetaxel, ifosfamide, and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma. Jpn J Clin Oncol 2015; 45: 281-5.
7. Taguchi S, Fukuhara H*, Azuma T, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Kume H, Igawa Y, Homma Y. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer. BMC Urol 2014; 14: 81.
6. Nose Y, Ishikawa A*, Taguchi S, Sato T, Tajima A, Uchida T. Pathology-based assessment of the treatment effect of high intensity focused-ultrasound for organ-confined prostate cancer. Jpn J Endourol 2014; 27: 207-9.
5. Taguchi S*, Nose Y, Sato T, Kobayashi T, Takaya K, Ishikawa A, Homma Y. Silicate urolithiasis during long-term treatment with zonisamide. Case Rep Med 2013; 2013: 629381.
4. Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T, Fukuhara H, Nishimatsu H, Ishikawa A, Kume H*, Homma Y. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy. Jpn J Clin Oncol 2013; 43: 923-8.
3. Taguchi S, Enomoto Y*, Homma Y. Bladder endometriosis developed after long-term estrogen therapy for prostate cancer. Int J Urol 2012; 19: 964-5.
2. Taguchi S*, Takahashi S, Iida K, Mizutani T, Yamaguchi K, Tominaga T, Niwa N, Yoshimi M, Takahashi T, Homma Y. Spermatic cord lymphoma: a case report and literature review. Case Rep Med 2012; 2012: 513707.
1. Taguchi S, Fujimura T*, Kume H, Homma Y. Zoledronic acid administration in aggressive castration-resistant prostate cancer. Asian Pac J Cancer Prev 2012; 13: 6539-40.

和文
7. 東原 英二*, 多武保 光宏, 山口 剛, 田口 慧, 福原 浩. 日本発の難病(常染色体優性多発性嚢胞腎)治療薬の開発. 腎臓内科・泌尿器科 2019; 9: 448-456.
6. 田口 慧*, 福原 浩, 井川靖彦, 佐々木和人, 田中敏明, 渡邉聡明. (特集: 攻めるか守るか 直腸癌手術の機能温存と拡大切除) 尿管の温存と合併切除. 手術 2017; 71: 1257-1264.
5. 福原 浩*, 田口 慧, 本間之夫. 遺伝子組換えウイルスを用いたがん治療開発. 泌尿器外科 2016; 29: 351-4.
4. 竹村光太郎, 田口 慧*, 高橋真太朗, 能勢頼人, 佐藤俊和, 石川 晃, 本間之夫. 尿管ステントの上方変位―症例報告と文献検索. 泌尿器外科 2014; 27: 1711-4.
3. 能勢頼人, 石川 晃*, 田口 慧, 佐藤俊和, 平石禎子, 岸田由起子, 田村浩一. 迷入魚骨に起因する尿膜管膿瘍の1例. 泌尿器外科 2013; 26: 1447-50.
2. 飯田勝之*, 富永登志, 水谷 隆, 山口千美, 高橋さゆり, 田口 慧, 植木哲雄, 宗像昭夫, 矢島愛治, 上條利幸. 三井記念病院における前立腺癌に対する初期内分泌療法としての酢酸クロルマジノンによるCombined Androgen Blockadeの検討. 泌尿器外科 2011; 24: 1563-8.
1. 田口 慧*, 山口千美, 高橋さゆり, 飯田勝之, 水谷 隆, 富永登志, 森 正也, 本間之夫. 高齢者に見られた精巣Leydig 細胞腫の1例. 泌尿器科紀要 2011; 57: 521-4.
所属学会 日本泌尿器科学会
日本泌尿器内視鏡学会
日本泌尿器腫瘍学会
日本老年泌尿器科学会
日本癌治療学会
日本癌学会
泌尿器科分子・細胞研究会
日本遺伝子細胞治療学会
米国臨床腫瘍学会(ASCO)
このページのトップへ

PAGE TOP